STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
A psychedelic drug candidate from Helus Pharma significantly helped people with major depression in a Phase 3 trial, the company said Monday, but a number of serious adverse events in the study raised questions about the safety of the treatment.
- At 12 weeks, the effect was largely maintained, with the treatment group seeing a 16.9-point reduction and the placebo group experiencing a 9.9-point reduction.
- Continue to STAT+ to read the full story….
- The differences between the two groups were all statistically significant.
Six weeks into the study, people taking the drug in addition to their standard antidepressants experienced a reduction of 19.5 points on a depression rating scale called the MADRS, while the placebo group had a 11.9-point reduction.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →